Last reviewed · How we verify
Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid (DERMOS)
Bullous pemphigoid is the most common type of bullous skin disease and is clinically characterized by clear-tense bullae, which result in post-bullous cutaneous erosions, altering the skin barrier. The treatment of this pathology consists of the application of high doses of topical corticosteroids (clobetasol propionate) for a prolonged period of at least 6 months. The main objective of this study is to demonstrate a change in bone mineral density at 6 months after initiation of treatment, in subjects with bullous pemphigoid and treated with topical corticosteroid.
Details
| Lead sponsor | Centre Hospitalier Universitaire, Amiens |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 50 |
| Start date | 2019-04-01 |
| Completion | 2024-04 |
Conditions
- Osteoporosis
- Bullous Pemphigoid
Interventions
- bone densitometry
- blood test
- radiographs of the thoracic and lumbar spine
- Clobetasol propionate
Primary outcomes
- Variation of the bone mineral density (BMD) expressed in g/cm² at the lumbar spine between baseline and the theorical end of the treatment. — 6 months after beginning of the treatment
Patients with bullous pemphigoid and treated with Clobetasol propionate will benefit from bone densitometry at the initiation of the treatment and at 6 months (theoretical end of the treatment).
Countries
France